Journal of Vaccine Research 2024, Vol.14, No.4, 157-169 http://medscipublisher.com/index.php/jvr 167 Jang Y., and Seong B.L., 2019, The quest for a truly universal influenza vaccine, Frontiers in Cellular and Infection Microbiology, 9: 344. https://doi.org/10.3389/fcimb.2019.00344 PMid:31649895 PMCid:PMC6795694 Joyce M.G., Wheatley A K., Thomas P.V., Chuang G.Y., Soto C., Bailer R.T., Druz A., Georgiev I.S., Gillespie R.A., Kanekiyo M., Kong W.P., Leung K., Narpala S.N., Prabhakaran M.S., Yang E.S., Zhang B., Zhang Y., Asokan M., Boyington J.C., Bylund T., Darko S., Lees C.R., Ransier A., Shen C.H., Wang L.S., Whittle J.R., Wu X.L., Yassine H.M., Santos C., Matsuoka Y., Tsybovsky Y., Baxa U., NISC Comparative Sequencing Program, Mullikin J.C., Subbarao K., Douek D.C., Graham B.S., Koup R.A., Ledgerwood J.E., Roederer M., Shapiro L., Kwong P.D., Mascola J.R., and McDermott A.B., 2016, Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses, Cell, 166(3): 609-623. https://doi.org/10.1016/j.cell.2016.06.043 PMid:27453470 PMCid:PMC4978566 Junkins R.D., Gallovic M.D., Johnson B.M., Collier M.A., Watkins-Schulz R., Cheng N., David C.N., McGee C.E., Sempowski G.D., Shterev I., McKinnon K., Bachelder E.M., Ainslie K.M., and Ting J.P.Y., 2018, A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination, Journal of Controlled Release, 270: 1-13. https://doi.org/10.1016/j.jconrel.2017.11.030 PMid:29170142 PMCid:PMC5808851 Kim E.H., Han G.Y., and Nguyen H., 2017, An adenovirus-vectored influenza vaccine induces durable cross-protective hemagglutinin stalk antibody responses in mice, Viruses, 9(8): 234. https://doi.org/10.3390/v9080234 PMid:28825679 PMCid:PMC5580491 Kim T., Bimler L., Ronzulli S.L., Song A.Y., Johnson S.K., Jones C.A., Tompkins S.M., and Paust S., 2022, A low-dose triple antibody cocktail against the ectodomain of the matrix protein 2 of influenza A is A universally effective and viral escape mutant resistant therapeutic agent, bioRxiv, 2022-04. https://doi.org/10.1101/2022.04.02.486847 Liao H.Y., Wang S.C., Ko Y., Lin K.I., Ma C., Cheng T.J., and Wong C.H., 2020, Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes, Proceedings of the National Academy of Sciences, 117(30): 17757-17763. https://doi.org/10.1073/pnas.2004783117 PMid:32669430 PMCid:PMC7395492 Liu C.C., Liu D.J., Yue X.Y., Zhong X.Q., Wu X., Chang H.Y., Wang B.Z., Wan M.Y., and Deng L., 2022, Chimeric virus-like particles co-displaying hemagglutinin stem and the C-Terminal fragment of dnak confer heterologous influenza protection in mice, Viruses, 14(10): 2109. https://doi.org/10.3390/v14102109 PMid:36298664 PMCid:PMC9610613 Liu J., Ren Z., Wang H., Zhao Y., Wilker P.R., Yu Z., Sun W.Y., Wang T.C., Feng N., Li Y.G., Wang H.L., Ji X.L., Li N., Yang S.T., He H.B., Qin C., GaoY.W., and Xia X., 2018, Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses, International Immunopharmacology, 63: 119-128. https://doi.org/10.1016/j.intimp.2018.07.011 PMid:30081250 Lo C., Misplon J. A., Li X., Price G., Ye Z., and Epstein S.L., 2021, Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice, Vaccine, 39(33): 4628-4640. https://doi.org/10.1016/j.vaccine.2021.06.072 PMid:34226103 Madsen A., and Cox R.J., 2020, Prospects and challenges in the development of universal influenza vaccines, Vaccines, 8(3): 361. https://doi.org/10.3390/vaccines8030361 PMid:32640619 PMCid:PMC7563311 Nachbagauer R., Feser J., Naficy A., Bernstein D.I., Guptill J., Walter E.B., Berlanda-Scorza F., Stadlbauer D., Wilson P.C., Aydillo T., Behzadi M.A., Bhavsar D., Bliss C., Capuano C., Carreño J.M., Chromikova V., Claeys C., Coughlan L., Freyn A.W., Gast C., Javier A., Jiang K., Mariottini C., McMahon M., McNeal M., Solórzano A., Strohmeier S., Sun W., Van der Wielen M., Innis B.L., García-Sastre A., Palese P., and Krammer F., 2021, A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial, Nature Medicine, 27(1): 106-114. https://doi.org/10.1038/s41591-020-1118-7 PMid:33288923 Nachbagauer R., Salaun B., Stadlbauer D., Behzadi M.A., Friel D., Rajabhathor A., Choi A., Albrecht R.A., Debois M., García-Sastre A., Rouxel R.N., Sun W., Palese P., Mallett C.P., Innis B.L., Krammer F., and Claeys C., 2019, Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts, NPJ Vaccines, 4(1): 51. https://doi.org/10.1038/s41541-019-0147-z PMid:31839997 PMCid:PMC6898674 Nerome K., Imagawa T., Sugita S., Arasaki Y., Maegawa K., Kawasaki K., Tanaka T., Watanabe S., Nishimura H., Suzuki T., Kuroda K., Kosugi I., and Kajiura Z., 2023, The potential of a universal influenza virus-like particle vaccine expressing a chimeric cytokine, Life Science Alliance, 6(1). https://doi.org/10.26508/lsa.202201548 PMid:36344085 PMCid:PMC9644419
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==